Dan adam cyp2c9 da vkorc1 Gene Polymorphism

Warfarin shine anticioagulant na baka na al'ada a cikin aikin asibiti a halin yanzu, wanda akasari ne wanda aka yi niyya ne don yin rigakafi da magani na theromboemmicics. Koyaya, Warfarin yana da iyakantaccen taga magani kuma ya bambanta da yawa tsakanin jinsi daban-daban da daidaikun mutane. Ƙididdigar sun nuna cewa bambancin tsayayyen kashi a cikin mutane daban-daban na iya zama fiye da sau 20. Haske na zubar da jini yana faruwa ne a cikin 15.2% na marasa lafiya suna ɗaukar warfarin kowace shekara, wanda 3.5% ci gaba da zafin jini mai zafi. Karatun Pharmacogenic ya nuna cewa kwayoyin polymorph na manufa enzyme vkorc1 da metabololen enzyme cyp2c9 na Warfarin muhimmiyar hujja ce ta haifar da bambanci a cikin kashi na warfarin. Warfarin wani takamaiman inhibitor na Vitamin K epoxide Redocting (VKORC1), kuma ta haka ne, yana hana wani abu game da aikin bitamin K kuma yana ba da rigakafin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta Babban adadin karatu ya nuna cewa Gene Polymorphism na VKORC1 mai mahimmanci shine mafi mahimmancin tsere da bambance-bambance na mutum a cikin kashi na da ake buƙata na warfarin. Warfararin yana motsa shi ta hanyar Cyp2c9, kuma halrts matuƙar metabolism na Warfarin. Mutane daban-daban suna amfani da warfarin suna da haɗari mafi girma (sau sau biyu zuwa sau biyu) na zubar jini a farkon amfani.